Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diphtheria toxin A is the **enzymatically active portion (fragment A) of diphtheria toxin**, a protein exotoxin produced by toxic strains of *Corynebacterium diphtheriae* following infection by a bacteriophage. The diphtheria toxin is a two-part (A+B) protein: **fragment A is responsible for the ADP-ribosylation and inactivation of elongation factor 2 (EF-2)**, which halts protein synthesis and results in cell death[9][12][11]. Diphtheria toxin A has been widely adapted as the **cytotoxic payload in recombinant fusion protein therapies (immunotoxins or fusion toxins)** for the targeted killing of malignant or pathological cells in cancer, autoimmune, and other diseases. It is not used clinically as a standalone drug but as a component in engineered therapeutics where the targeting domain directs the cytotoxic A fragment to specific cell populations[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphtheria toxin A.